肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Merrimack在中期研究失败后停止开发实验性胰腺癌治疗药物

2018-06-26 MedSci MedSci原创

胰腺癌Merrimackistiratumab
关注

Merrimack制药公司在II期临床试验（CARRIE研究）中，实验性转移性胰腺癌治疗药物istiratumab（也被称为MM-141）未能达到其主要或次要临床终点。根据这些结果，Merrimack将不会投入更多资源来开发istiratumab。

Merrimack制药公司在II期临床试验（CARRIE研究）中，实验性转移性胰腺癌治疗药物istiratumab（也被称为MM-141）未能达到其主要或次要临床终点。根据这些结果，Merrimack将不会投入更多资源来开发istiratumab。

CARRIE研究涉及88例先前未经治疗的转移性胰腺癌和高血清游离胰岛素样生长因子-1水平的患者，这是大约50％的胰腺癌患者的普遍生物标志物。患者随机接受istiratumab或安慰剂治疗，联合纳他紫杉醇和吉西他滨。主要终点是无进展生存期，次要目标包括客观缓解率、疾病控制率、缓解持续时间、总体存活率和安全性

Merrimack指出，在所有分析的亚组中，istiratumab缺乏有效性的结论是一致的，CARRIE研究的完整数据将在未来的研究会议上提交。Merrimack首席执行官理查德·彼得斯表示：“虽然这些结果令人失望，但我们的重点仍然放在另外两个实验性药物（MM-121和MM-310）上，预计2018年将有数据得出”。在SHERBOC试验中，MM-121（也被称为seribantumab），处于II期开发阶段，用于非小细胞肺癌患者以及转移性乳腺癌患者的治疗，而MM-310正在进行实体瘤患者的早期检测。


原始出处：

http://www.firstwordpharma.com/node/1574461#axzz5JX2NWGqk

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040723, encodeId=92022040e2300, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue Oct 02 11:39:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921714, encodeId=a6381921e14ae, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Apr 17 13:39:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996185, encodeId=5a09199618500, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Oct 18 04:39:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703586, encodeId=4fc61e03586e4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Mon Jan 21 11:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
    2018-10-02 lujian

    #实验性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2040723, encodeId=92022040e2300, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue Oct 02 11:39:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921714, encodeId=a6381921e14ae, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Apr 17 13:39:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996185, encodeId=5a09199618500, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Oct 18 04:39:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703586, encodeId=4fc61e03586e4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Mon Jan 21 11:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
    2019-04-17 周虎

    #治疗药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2040723, encodeId=92022040e2300, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue Oct 02 11:39:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921714, encodeId=a6381921e14ae, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Apr 17 13:39:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996185, encodeId=5a09199618500, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Oct 18 04:39:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703586, encodeId=4fc61e03586e4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Mon Jan 21 11:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
    2018-10-18 yb6560

    #MAC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2040723, encodeId=92022040e2300, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue Oct 02 11:39:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921714, encodeId=a6381921e14ae, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Apr 17 13:39:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996185, encodeId=5a09199618500, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Oct 18 04:39:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703586, encodeId=4fc61e03586e4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Mon Jan 21 11:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=)]
    2019-01-21 surilei

    #ERR#

    0

相关资讯

这种“胃痛”要小心胰腺癌！如何撕破胰腺癌的层层伪装？

5月25日，我接诊了一个面容憔悴的56岁男性患者。他于半年前感到上腹不规则隐痛，并时常有嗳气，反酸、饱胀等症状。患者先后做了胃镜检查和碳-13呼气试验，发现有慢性浅表性胃炎，幽门螺旋杆菌感染，长期服用了兰索拉唑、莫沙必利、铋剂、根除幽门螺旋杆菌的治疗胃病药物，然而消化不良症状并未见明显减轻，而且上腹部疼痛越来越厉害，有时连腰背都开始疼，体重也下降了将近30斤。根据经验，我高度怀疑胰腺疾病，说

Nature：治疗胰腺癌，我们之前的做法可能错了？

近日，顶尖学术期刊《自然》在线刊登了一篇论文，指出了一个不幸的事实。在有“癌症之王”之称的胰腺癌面前，我们之前的处理方法，可能有一个误区。

Gastroenterology：新发糖尿病患者胰腺癌风险预测模型

根据糖尿病确诊时的体重、血糖以及年龄可以预测新发糖尿病患者的胰腺癌风险，该模型为胰腺癌早期诊断提供了依据

Cancer Res：上海交大学者发现克制胰腺癌的新靶标

外泌体是细胞外泌囊泡中体积较小的一种，近年来研究表明外泌体中包含细胞特异的蛋白、脂质和核酸，能作为信号分子传递给其他细胞改变其功能。外泌体是肿瘤细胞和微环境对话的重要介导因子，但是对于胰腺癌来说外泌体如何在低氧条件下调节肿瘤发育其机制仍不明确。

胰腺癌综合诊治指南（2018版）

胰腺癌发病呈快速上升趋势。2017年美国癌症协会发布的数据显示，美国胰腺癌新发病例数男性列第11位、女性列第8位，居恶性肿瘤死亡率第4位1。中国国家癌症中心最新统计数据也显示，胰腺癌位列中国城市男性恶性肿瘤发病率的第8位，居大城市（北京、上海）人群恶性肿瘤死亡率的第5位。

JAMA：胰腺癌风险基因突变研究

研究发现，6种基因突变人群的胰腺癌风险增加，上述突变人群占所有胰腺癌、家族胰腺癌以及非家族胰腺癌患者的比例分别为5.5%、7.9%和5.2%